BioNeutra Global Bilan de santé

Santé financière contrôle des critères 1/6

BioNeutra Global possède un total de capitaux propres de CA$-7.8M et une dette totale de CA$7.5M, ce qui porte son ratio d'endettement à -96.3%. Son actif total et son passif total sont CA$14.4M et de CA$22.2M.

Informations clés

-96.3%

Ratio d'endettement

CA$7.51m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CA$355.24k
Fonds propres	-CA$7.80m
Total du passif	CA$22.16m
Total des actifs	CA$14.36m

Mises à jour récentes de la santé financière

Recent updates

Calculating The Fair Value Of BioNeutra Global Corporation (CVE:BGA)

Dec 30

A Look At The Fair Value Of BioNeutra Global Corporation (CVE:BGA)

Aug 24

We Discuss Why BioNeutra Global Corporation's (CVE:BGA) CEO Compensation May Be Closely Reviewed

Sep 15

Is BioNeutra Global (CVE:BGA) Using Too Much Debt?

Jul 12

Is BioNeutra Global (CVE:BGA) Weighed On By Its Debt Load?

Mar 29

Does BioNeutra Global (CVE:BGA) Have A Healthy Balance Sheet?

Dec 14

Analyse de la situation financière

Passif à court terme: BGA a des fonds propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à court terme.

Passif à long terme: BGA a des capitaux propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: BGA a des fonds propres négatifs, ce qui est une situation plus grave qu'un niveau d'endettement élevé.

Réduire la dette: BGA a des capitaux propres négatifs, nous n'avons donc pas besoin de vérifier si sa dette a diminué au fil du temps.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BGA dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: BGA dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 26.7 % chaque année

BioNeutra Global Bilan de santé

Santé financière contrôle des critères 1/6

Informations clés

Mises à jour récentes de la santé financière

Is BioNeutra Global (CVE:BGA) Using Too Much Debt?

Is BioNeutra Global (CVE:BGA) Weighed On By Its Debt Load?

Does BioNeutra Global (CVE:BGA) Have A Healthy Balance Sheet?

Recent updates

High number of new directors

Second quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.027 loss in 2Q 2023)

BioNeutra Global Corporation, Annual General Meeting, Sep 09, 2024

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)

Less than half of directors are independent

Full year 2023 earnings released: CA$0.05 loss per share (vs CA$0.063 loss in FY 2022)

BioNeutra Global Corporation Appoints Stephen Jakeway as Chief Operating Officer

Less than half of directors are independent

Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.027 loss in 3Q 2022)

Less than half of directors are independent

BioNeutra Global Corporation Appoints Mr. Bill Smith to the Board of Directors

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

BioNeutra Global Corporation Announces Executive Changes

Less than half of directors are independent

Full year 2022 earnings released: CA$0.06 loss per share (vs CA$0.061 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Calculating The Fair Value Of BioNeutra Global Corporation (CVE:BGA)

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.016 loss in 3Q 2021)

Less than half of directors are independent

Now 40% undervalued

A Look At The Fair Value Of BioNeutra Global Corporation (CVE:BGA)

Second quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.001 loss in 2Q 2021)

Less than half of directors are independent

BioNeutra Global Corporation Appoints Ross Montagano as Chief Operating Officer

Less than half of directors are independent

First quarter 2022 earnings released

BioNeutra Global Corporation, Annual General Meeting, Jul 08, 2022

Full year 2021 earnings released: CA$0.06 loss per share (vs CA$0.08 loss in FY 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Less than half of directors are independent

We Discuss Why BioNeutra Global Corporation's (CVE:BGA) CEO Compensation May Be Closely Reviewed

Is BioNeutra Global (CVE:BGA) Using Too Much Debt?

First quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.024 loss in 1Q 2020)

Chairman Peter Watson has left the company

Is BioNeutra Global (CVE:BGA) Weighed On By Its Debt Load?

New 90-day high: CA$0.30

Does BioNeutra Global (CVE:BGA) Have A Healthy Balance Sheet?

Third quarter 2020 earnings released: CA$0.001 loss per share

Bioneutra Global Corporation Announces Executive Appointments

Bioneutra Global Corporation Appoints Bill Smith as Senior Vice President

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines